Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
•
Medical Oncology
How would you approach treatment of recurrent endometrial cancer (lung) with areas of squamous differentiation, ER/PR+ and MS-stable?
Prior TAH done 4 years ago, no adjuvant treatment at that time.
Related Questions
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
What is your preferred first line systemic treatment for recurrent, metastatic, low grade, ER/PR+ pMMR endometrioid endometrial carcinoma?
When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?
Would you offer pelvic radiation in a patient with Stage IIIC endometrial cancer who has Crohn's disease and a permanent ileostomy?
Would you treat endometrioid adenocarcinoma arising from an endometriosis lesion in a patient with prior hyst/BSO like an ovarian or endometrial primary?